(Total Views: 239)
Posted On: 09/22/2021 12:51:56 PM
Post# of 63
Gilead announced results from a double-blind Phase 3 clinical trial which showed that early administration of Remdesivir reduced hospitalizations for Covid-19 by 67%.
More importantly for Matinas Biopharma (MTNB), Gilead also announced it is developing a novel oral treatment for Remdesivir, and hoped to file an INDA with the FDA in early 2022.
Given that, according to Matinas' CEO, Jerry Jabbour, the NIH placed Matinas' LNC version of Remdesivir at the top of the queue, it would be fair to infer that this is the "novel oral treatment" for Remdesivir announced by Gilead.
If so, MTNB will be off to the races when the INDA application is filed with the FDA in early 2022.
More importantly for Matinas Biopharma (MTNB), Gilead also announced it is developing a novel oral treatment for Remdesivir, and hoped to file an INDA with the FDA in early 2022.
Given that, according to Matinas' CEO, Jerry Jabbour, the NIH placed Matinas' LNC version of Remdesivir at the top of the queue, it would be fair to infer that this is the "novel oral treatment" for Remdesivir announced by Gilead.
If so, MTNB will be off to the races when the INDA application is filed with the FDA in early 2022.
(1)
(0)
The Lawman
style="color:red">The Lawman"color:red">The Lawman:red">The LawmanThe Lawmanspan>Lawmanawmanimg]
